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Erythrocytes are exceptionally suited for analysis of non-exocytotic release mechanisms of ATP,
because these cells under physiological conditions lack vesicles. Previous studies have indicated,
that Pannexin1 (Panx1) provides a key ATP permeation pathway in many cell types, including
human and frog erythrocytes. Here we show that erythrocytes of Panx1/mice lend further support
to this conclusion. However, ATP release, although attenuated, was still observed in Panx1/mouse
erythrocytes. In contrast to Panx1+/+ cells, this release was not correlated with uptake of extracellu-
larly applied dyes, was insensitive to Panx1 channel blockers, and was inhibited by dipyridamole
and stimulated by iloprost. Thus, in erythrocytes, two independent pathways mediate the release
of ATP. We also show that glyburide is a strong inhibitor of Panx1 channels.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The role of ATP as a signaling molecule is now well established
[1,2]. A variety of physiological functions are regulated by ATP,
including control of ciliary beat in airway epithelial cells, control
of peripheral oxygen supply and trigger of immune response [3–
5]. Several mechanisms mediate ATP release and include vesicular
release, channel and/or transport mediated release and lytic loss of
ATP from cells through compromised membranes. In many cells
these mechanisms co-exist and thereby hamper mechanistic anal-
ysis, because interference with one release mechanism typically
leaves another intact. Erythrocytes are exceptionally suited for
mechanistic analysis of ATP release, because these cells lack vesi-
cles and consequently exocytotic ATP release. Erythrocytes release
ATP in low oxygen environment and in response to shear stress
[4,6]. The physiological function of this ATP release is to control
oxygen supply via endothelial production and release of NO and
other relaxing factors leading to vasodilation [4,7–9].
Like in many other cell types, ATP release from human and frog
erythrocytes is correlated with uptake of extracellularly applied
dyes [10–13], suggesting that the release mechanism involves a
large pore which allows the counter-ﬂux of ATP and dyes. Both,
dye uptake and ATP release by erythrocytes can be attenuated by
inhibitors of Panx1 channels [12,13]. Furthermore, erythrocyteschemical Societies. Published by E
Physiology and Biophysics,
6430, Miami, FL 33101, USA.express Panx1 abundantly in their plasma membrane [10,11] sug-
gesting a role of Panx1 in ATP release from these cells.
For an independent test of Panx1 involvement in ATP release by
erythrocytes we used here Panx1 deﬁcient mice. While ATP release
from Panx1/ erythrocytes was attenuated as compared to
Panx1+/+ erythrocytes, a substantial residual release was still
observed. This component was insensitive to Panx1 blockers but
was inhibited by dipyridamole, a drug known to inhibit nucleoside
transport [14]. Surprisingly, the CFTR inhibitor, glyburide, which in
previous studies was shown to reduce the amount of ATP released
fromerythrocytes [6,15–17], is shownhere to block Panx1 channels.
2. Materials and methods
2.1. Preparation of cells
Mice were anesthesized with isoﬂuorane. After decapitation,
mouse blood was collected in 5–10 ml Krebs solution containing
5 mM EGTA. The collected blood was centrifuged at low speed to
remove the plasma, leukocytes and platelets. The puriﬁed erythro-
cytes were washed three times by low-speed centrifugation before
being suspended at 20% hematocrit (2% in the experiments with
dipyridamole) in Krebs as stock. To assure equal number of eryth-
rocytes in the various samples, light transmittance was determined
spectrometrically and Krebs solution was added if needed.
Preparation of oocytes and electrophysiological recording were
performed as described [18]. A mouse pannexin1 construct was
kindly provided by Dr. Rolf Dermietzel (University of Bochum),lsevier B.V. All rights reserved.
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Fig. 1. (a) Example of a Western blot of erythrocyte membranes of Panx1+/+ and
Panx1/ mice. The double band characteristic for Panx1 at 50 kDa was present in
Panx1+/+ erythrocytes but not in Panx1/ cells. (b) ATP release from Panx1+/+
(white bars) and Panx1/ (grey bars) erythrocytes. ATP release, as determined with
a luciferase assay, is stimulated by hypotonic K+ solution (K+) more profoundly in
Panx1+/+ erythrocytes than in Panx1/ erythrocytes. The Panx1 channel inhibitor
probenecid (prob, 1 mM) attenuated ATP release in Panx1+/+ cells but not
signiﬁcantly (P > 0.05) in Panx1/ cells.
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versity). The plasmid containing mouse Pannxin1 in pCS2 was lin-
earized with Not I. In vitro transcription were performed with
polymerases SP6, using the Message Machine kit (Ambion, Austin,
TX). mRNAs were quantiﬁed by absorbance (260 nm), and the pro-
portion of full-length transcripts was checked by agarose gel elec-
trophoresis. In vitro transcribed mRNAs (40 nl) were injected into
Xenopus oocytes. Cells were kept in regular Ringer solution OR2
(82.5 mM NaCl, 2.5 mM KCl, 1 mM Na2HPO4, 1 mM MgCl2, 1 mM
CaCl2 and 5 mM HEPES) with 10 mg/ml antibiotics streptomycin.
2.2. Pannexin1 knock-out mouse generation
Hemizygote Panx1-knockout (KO) ﬁrst (Panx1tm1a(KOMP)Wtsi)
mice, in the C57Bl6 background, was generated and purchased from
KOMP at UCDavis, an NIH initiative. Hemizygotes were bred till
homozygosity andmaintainedas Panx1+/+ andPanx/ in the animal
facility at Albert Einstein College of Medicine. As previously de-
scribed [19], Panx1KOﬁrstwere genotypedby tail PCRusing 4 prim-
ers (1: 50GAGATGGCGCAACGCAATTAAT30; 2: 50CTGGCTCTCATA
ATTCTTGCCCTG30; 3: 50 CTGTATCACACAACCACTTCAGAGAAGG30;
4: 50GAGCTGACCCCTTTCCATTCAATAG30). Thewild typePanx1allele
was targetedby primers3 and4 and identiﬁed as a 579 bp amplicon,
while the transgene was targeted by primers 1 and 2 and identiﬁed
asa381 bpampliconMice lackingPanx1areviable, fertile anddonot
display gross morphological defects of major organs.
2.3. Western blot
Erythrocytes derived from 2 Panx1+/+ and 3 Panx1/ adult mice
were lysed in HEPES buffered H2O. Membranes were pelleted by
centrifugation at 100000g. After resuspension, this step was re-
peated until the pellet was colorless. The pellet was taken up in ly-
sis buffer (150 mM NaCl; 10 mM Tris–base; 1% TritonX-100;
protease inhibitor cocktail; pH 7.4) and total protein measured
using the BCA reagents (Thermo Scientiﬁc). Samples were electro-
phoresed in 4–20% mini-gels. After transfer of proteins to nitrocel-
lulose membranes and one hour incubation in blocking phosphate
buffered solution (PBS) containing 0.5% Tween-20 and 2% skinned
milk, blotting was performed for two hours at room temperature
(RT) using anti-Panx1 (1:1000) antibody 4515 ([11,20] and anti-
beta actin (1:2000) antibodies After washes with PBS-Tween-20,
membranes were incubated with goat anti-chicken or goat anti-
mouse HRP conjugated secondary antibodies (1:2000; Santa Cruz
Technology) for one hour at RT. Visualization of bands was per-
formed using X-ray ﬁlm and a developer.
2.4. Electrophysiology
Whole cell membrane current of single oocytes was measured
using a two-electrode voltage clamp and recorded with a chart re-
corder. Both voltage-measuring and current-passing microelec-
trodes were pulled with a vertical puller (Kopf) and ﬁlled with
3 M KCl. The recording chamber was perfused continuously with
solution. Membrane conductance was determined using voltage
pulse. Oocytes expressing mouse pannexin1 were held at 60 or
50 mV, and 5 s pulses to +20 or +50 mV were applied to tran-
siently open the channels.
Glyburide and dipyridamole were obtained from Sigma–Aldrich
and iloprost from Cayman. Stock solutions of glyburide and dipyrid-
amolewere inDMSOand iloprostwasdissolved in aqueous solution.
2.5. ATP-release assay
ATP ﬂux was determined by luminometry. The mouse erythro-
cytes were pre-incubated in Krebs solution with or without(control) drugs for 10 min, and aliquots of 10 ll were added into
100 ll stimulation solutions (150 mM KGlu or 1:1 diluted with
water to yield hypotonic 75 mM KGlu) for 10 min. After 1-min
low-speed centrifugation (100g), 50 ll of supernatant were
used with a luciferase assay (Promega, Madison, USA) to determine
the ATP level. Oocytes, two days after injection of mouse Panx1
messenger RNA were pretreated in OR2 solution with and without
drugs for 10 min and stimulated by incubation in OR2 solution
(negative control), KGlu solutions (positive control), KGlu solution
with drug, respectively, for 10 min. The supernatant was collected
and assayed with luciferase/luciferin. A calibration curve was pre-
pared with ATP supplied with the assay kit to assure that measure-
ments were within the linear range of the assay.
2.6. Dye uptake
Erythrocytes were incubated in Krebs and hypotonic KGlu solu-
tions containing 1 mM 5,6-carboxyﬂuorescein for 10 min, then
washed repeatedly with Krebs solution before viewing under epi-
ﬂuorescence microscopy. Fluorescence images were captured
using a Nikon inverted microscope equipped with 40X objective,
488/512 nm ﬁlter sets and Metaﬂuor software.
3. Results
3.1. ATP release
Pannexin1 channels [21] can be opened by mechanical stress
and by increased extracellular K+ concentration independent of
the cell membrane potential [22–24]. Fig. 1 shows that ATP release
from Panx1+/+ mouse erythrocytes was stimulated by a hypotonic
K+ solution and the release was attenuated by the Panx1 channel
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Fig. 2. (a) Iloprost (25 lM) stimulated ATP release in Panx1+/+ (white bars) and
Panx1/ (grey bars) erythrocytes to similar levels. The iloprost-induced release
remained unaffected by probenecid (1 mM). (b) Dipyridamole inhibited the
iloprost-induced ATP release by Panx1+/+ mouse erythrocytes. (c) ATP release by
Panx1+/+ mouse erythrocytes induced by hypotonic K+ solution (KGlu) was inhibited
by dipyridamole or by probenecid (1 mM). The combination of the drugs was not
more effective than either drug alone. Note, that different hematocrits were used
for part (a) (20%) as compared to parts (b and c) (2%). Signiﬁcance levels (Anova
with Newman–Keul’s post test): ⁄<0.05, ⁄⁄<0.01.
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where Panx1 channel inhibitors almost completely abolish ATP re-
lease [11,25], a substantial release remained in mouse erythrocytes
after probenecid treatment. This observation suggests the exis-
tence of an alternate ATP release pathway to Panx1. As indicated
by Panx1/ erythrocytes (Fig. 1), this alternate pathway was also
activated by hypotonic K+. However, in contrast to Panx1+/+ eryth-
rocytes, the amount of ATP released was lower and no signiﬁcant
inhibition of ATP release by probenecid was observed. A probene-
cid-insensitive ATP release from human erythrocytes has been re-
ported previously for iloprost-induced release [25]. Fig. 2a shows
that iloprost-stimulated ATP release by mouse erythrocytes to sim-
ilar levels regardless whether Panx1 was present (Panx1+/+) or ab-
sent (Panx1/) and that probenecid had no effect on this process
in either type of erythrocyte.
3.2. Effect of dipyridamole
In a screening test on Panx1 expressing oocytes we have ob-
served that drugs reported in the literature to affect non-vesicular
ATP release also affected Panx1 currents. The Panx1 inhibiting
drugs include probenecid, which hitherto had been considered to
be a speciﬁc transport inhibitor, and also connexin mimetic pep-
tides as off target effect [13,26]. One drug, however, that is well doc-
umented to inhibit ATP release and nucleoside ﬂux, dipyridamole
[4,27], did not affect Panx1 channels. We, therefore, tested whether
the second, probenecid insensitive component of ATP release by
erythrocytes was sensitive to dipyridamole. As shown in Figs. 2b
and 3a, dipyridamole attenuated iloprost-induced ATP release but
did not affect Panx1 currents. The effect of dipyridamolewas not re-
stricted to iloprost-induced ATP release but also included the hypo-
tonic K+-induced release as shown in Fig. 2c. This indicates that
hypotonic K+ stimulates two separate ATP release pathways, one
sensitive to probenecid and one sensitive to dipyridamole. In that
case, onewould assume that the effects of these two drugs are addi-
tive. However, no additive effect was observed (Fig. 2c). Because the
data with Panx1/ cells unequivocally demonstrate, that Panx1
cannot be the cause of iloprost-induced ATP release, the lack of
additive effects of probenecid and dipyridamole on hypotonic K+-
induced ATP releasemust have a different explanation than compe-
tition of the drugs on one single target. We, therefore, tested the
effects of the two drugs onmouse Panx1 currents. Given separately,
probenecid inhibited Panx1 currents while dipyridamole had no
effect on the currents. When the drugs were combined, the inhibi-
tory effect was signiﬁcantly lower than that mediated by probene-
cid alone (Fig. 3). Thus, it appears that the drugs interact. However,
presently it is unclear where this interaction takes place. It could be
a direct interaction of probenecid with dipyridamole in solution,
thereby reducing the effective concentrations at their respective
targets, or there could be interference at the targets. For example,
dipyridamole, while by itself not interfering with Panx1 currents
could compete at the probenecid binding site of Panx1 and conse-
quently attenuate the inhibitory action of probenecid.
3.3. Uptake of extracellular tracer molecules
A hallmark of non-vesicular (presumably Panx1-mediated) ATP
release is the correlated uptake of extracellularly applied tracer
molecules. It has been demonstrated in many cell types, including
erythrocytes [10–13], that dyes with an exclusion limit >1 kDa are
taken up by cells under conditions similar to those inducing ATP
release. As shown in Fig. 4, mouse Panx1+/+ erythrocytes exhibited
uptake of carboxyﬂuorescein when stimulated with hypotonic K+.
In contrast, Panx1/ erythrocytes did not take up the dye under
the same experimental conditions. Similarly, no dye uptake was
observed, when ATP release was stimulated with iloprost inPanx1/ cells. These data show, that the Panx1 mediated, proben-
ecid sensitive ATP release pathway allows the concomitant uptake
of extracellular dyes. In contrast, the iloprost-induced/dipyridam-
ole sensitive ATP release pathway does not allow the entry of
extracellular molecules in a similar size range as ATP. Carboxyﬂuo-
rescein has an abaxial diameter of about 9 Å as compared to 12 Å
for ATP and thus should be small enough for passage through a
non-selective, ATP permeable channel. Aside from its effect on
ATP release, dipyridamole is known as a nucleoside transport
inhibitor [14]. The absence of dye ﬂux in the iloprost-induced
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Fig. 3. (a) Panx1 channel currents in oocytes expressing mouse Panx1 exogenously
were inhibited by probenecid (1 mM) but remained unaffected by dipyridamole
(10 lM). The inhibition by probenecid was less pronounced when dipyridamole
was also present. Currents were induced by voltage pulses from 60 to +20 mV. The
traces were selected from a continuous record from the same oocyte, The interval
between the traces was 30 min (for full recovery from the probenecid exposure). (b)
Quantitative analysis of current inhibition by probenecid (1 mM) in the absence and
presence of dipyridamole. Mean ± SE are shown, ⁄P < 0.05.
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Fig. 4. Hypotonic K+ solution (K+) stimulated the uptake of extracellularly applied
carboxyﬂuorescein in Panx1+/+ (wt) erythrocytes but not in Panx1/ (KO) eryth-
rocytes. Iloprost (25 lM) stimulation of Panx1/ erythrocytes did not result in
uptake of the dye.
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that provided by Panx1. The latter is in the form of a large, non-
selective pore that below the exclusion limit of 1500 Daltons
[26] does not discriminate by size or charge among molecules for
transit through the channel. The dipyramidole sensitive pathway
consequently is either an ATP selective channel or a transporter
(or shares key features with a transporter).3.4. Glyburide (glibenclamide) inhibits the Panx1 channel
ATP release by erythrocytes has been reported to involve the cys-
tic ﬁbrosis transmembrane conductance regulator (CFTR). Origi-
nally, it had been considered that CFTR provides the permeation
pathway for ATP [28], however, the lack of ATP permeability of the
CFTR channel excludes this possibility [29]. Nevertheless, the CFTR
inhibitor glyburide (glibenclamide) does interfere with the release
of ATP [6] and of epoxyeicosatrienoic acids [15]. Here we tested
whether glyburide may have additional targets in the erythrocyte
cell membrane. Speciﬁcally, because Panx1 channels evidently pro-
vide a permeation pathway for ATP, we tested whether glyburide
inhibits ATP ﬂux through Panx1 directly. Fig. 5 shows that glyburide
attenuated Panx1 currents in oocytes expressing the protein exoge-
nouslywith an EC50 of 45 lM. Furthermore, glyburide impaired ATP
release from Panx1 expressing oocytes in the same concentration
range where current inhibition was observed (Fig. 5d).4. Discussion
It appears that erythrocytes release ATP via two independent
pathways, one involving the channel formed by Panx1 and another
permeation mechanism that is either a highly selective channel or
a type of transporter. The contributions of these release mecha-
nisms may vary in different species as the pannexin1 blockers have
a more pronounced effect in human erythrocytes [11,25] than ob-
served here in mouse erythrocytes. Low oxygen, the prime physio-
logical stimulus for ATP release by erythrocytes, seems to
exclusively activate the Panx1 mediated release [10,11,25]. The
prostaglandin metabolite, iloprost, exclusively activates the alter-
nate, probenecid insensitive and dipyridamole sensitive, pathway.
Stimulation of ATP release by mouse erythrocytes with hypotonic
K+ solution, however, activated both permeation pathways. It re-
mains to be determined, which physiological role the non-Panx1
pathway exerts. In erythrocytes, the iloprost inducible, dipyridam-
ole sensitive pathway may be the only alternative to Panx1 chan-
nels for ATP release. However, the repertoire of most other cells
for different ATP release mechanisms is larger. Exocytotic ATP re-
lease is well established and may be the exclusive release mecha-
nism at nerve terminals, where ATP is co-packaged and co-released
with different transmitter substances. In many cell types, including
astrocytes and airway epithelial cells, exocytotic release of ATP co-
exists with the release through Panx1 channels and maybe other
permeation pathways.
Glyburide, also known as glibenclamide, binds with high afﬁnity
to the SUR subunit of ATP regulated potassium channels [30,31].
This effect underlies the therapeutic beneﬁt of glyburide in type 2
diabetes. At higher (micromolar) concentrations, glyburide also
inhibits members of the ATP binding cassette (ABC) transporter
family, including CFTR [32,33]. Here we show, that glyburide in
the micromolar concentration range also inhibits Panx1 currents
as well as Panx1mediated ATP release. Consequently, effects of gly-
buride on ATP release cannot be used as evidence for an involve-
ment of CFTR in the ATP release mechanism.
Recently it has been found that glyburide also affects innate
immunity by inhibiting the inﬂammasome in various settings
[34–37]. Typically, this is taken as evidence, that a key step in
inﬂammasome activation is a potassium efﬂux [38–40]. However,
the concentrations of glyburide required to inhibit activation of cas-
pase and release of cytokines from various types of cells is 3 orders
of magnitude higher than that for inhibition of potassium channels.
Thus an alternate target for the drug is likely to mediate the inhib-
itory effect on the inﬂammasome. With the identiﬁcation of Panx1
as a target of glyburide, this issue has to be reevaluated, in
particular because Panx1 is an elemental part of the inﬂammasome
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Fig. 5. (a) Membrane currents in oocytes expressing mouse Panx1 induced by voltage pulses from 50 to +50 mV. Glyburide (glibenclamide) attenuated the currents in a
dose-dependent fashion, n = 3–4. (b) Connexin 46 currents in oocytes were not affected by glyburide. (c) Dose–response relationship of Panx1 current inhibition by glyburide.
(d) ATP release by Panx1 expressing oocytes was stimulated by 150 mM potassium gluconate solution (KGlu) and inhibited by glyburide (100 lM).
3434 F. Qiu et al. / FEBS Letters 585 (2011) 3430–3435activationmechanism [24,41,42]. This point is further strengthened
by the observation that the inhibition of Panx1 channel currents
and of Panx1mediated ATP release occurred in the same concentra-
tion range as needed for inhibition of inﬂammasome activation.Acknowledgements
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